Chemed (CHE) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $6.06
- EPS estimate
- $5.60
- EPS surprise
- +8.21%
- Revenue surprise
- +1.24%
- Revenue
- $673.3M
- Revenue estimate
- $665.0M
- Reported
- Jul 28, 2026
Chemed reported Q2 2026 results on July 28, 2026. Earnings per share were $6.06, ahead of the $5.60 estimate by 8.21%. Revenue was $673.3 million against a $665.0 million estimate. Compared with Q2 2025, EPS rose about 41.9% from $4.27, the lowest quarter in the table, and revenue rose about 8.8% from $618.8 million. Revenue was the highest in the table.
Annual EPS rose from $19.76 in 2022 to $21.45 in 2023 and $23.14 in 2024, then fell about 6.7% to $21.59 in 2025. The first half of 2026 adds up to $11.71, about 18.3% more than $9.90 a year earlier. Q4 has been the strongest quarter in each full year shown, and Q4 2024's $6.83 is the high in the table. Revenue has grown more steadily, from $2.14 billion in 2022 to $2.53 billion in 2025. Chemed beat the EPS estimate in 13 of the last 20 quarters, though it missed in three straight quarters from Q2 to Q4 2025 before beating again in 2026.
Chemed reported Q3 results between October 25 and October 31 in each of the past five years. That points to late October 2026 for the next report.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 28, 2026 | $5.60 | $6.06 | +8.21% | $673.3M | SEC |
| Q1 2026 | Apr 23, 2026 | $5.30 | $5.65 | +6.55% | $657.5M | SEC |
| Q4 2025 | Feb 25, 2026 | $7.03 | $6.42 | −8.68% | $639.3M | SEC |
| Q3 2025 | Oct 28, 2025 | $5.37 | $5.27 | −1.77% | $624.9M | SEC |
| Q2 2025 | Jul 29, 2025 | $5.12 | $4.27 | −16.60% | $618.8M | SEC |
| Q1 2025 | Apr 23, 2025 | $5.55 | $5.63 | +1.50% | $646.9M | SEC |
| Q4 2024 | Feb 26, 2025 | $6.78 | $6.83 | +0.69% | $640.0M | SEC |
| Q3 2024 | Oct 29, 2024 | $5.65 | $5.64 | −0.09% | $606.2M | SEC |
| Q2 2024 | Jul 24, 2024 | $5.59 | $5.47 | −2.20% | $595.9M | SEC |
| Q1 2024 | Apr 24, 2024 | $5.48 | $5.20 | −5.11% | $589.2M | SEC |
| Q4 2023 | Feb 27, 2024 | $6.25 | $6.60 | +5.60% | $585.9M | SEC |
| Q3 2023 | Oct 25, 2023 | $4.90 | $5.32 | +8.57% | $564.5M | SEC |
| Q2 2023 | Jul 26, 2023 | $5.09 | $4.71 | −7.41% | $553.8M | SEC |
| Q1 2023 | Apr 26, 2023 | $4.81 | $4.82 | +0.21% | $560.2M | SEC |
| Q4 2022 | Feb 23, 2023 | $5.31 | $5.39 | +1.44% | $546.7M | SEC |
| Q3 2022 | Oct 31, 2022 | $4.65 | $4.74 | +2.01% | $526.5M | SEC |
| Q2 2022 | Jul 27, 2022 | $4.78 | $4.84 | +1.33% | $531.3M | SEC |
| Q1 2022 | Apr 26, 2022 | $4.47 | $4.79 | +7.08% | $530.5M | SEC |
| Q4 2021 | Feb 24, 2022 | $5.08 | $5.25 | +3.41% | $541.0M | SEC |
| Q3 2021 | Oct 28, 2021 | $4.49 | $5.06 | +12.69% | $538.7M | SEC |
Quarterly revenue
Frequently asked questions
When did Chemed (CHE) last report earnings?
Chemed last reported on Jul 28, 2026, covering fiscal Q2 2026.
Did CHE beat earnings estimates?
Yes. Chemed reported EPS of $6.06 for Q2 2026 against a $5.60 estimate — a 8.21% beat.
How much revenue did CHE report last quarter?
Chemed reported $673.3M in revenue for Q2 2026, against a consensus estimate of $665.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.